Results 201 to 210 of about 72,117 (255)

Rbm20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure (HFpEF). [PDF]

Cardiovasc Res
Methawasin M, Meinke S, Radke MH, Farman GP, Hourani Z, Smith JE, Guo W, Granzier H, Gotthardt M.   +8 more
europepmc   +1 more source

Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Inducible CRISPR/Cas systems enable spatiotemporal genome editing in precision oncology. Chemical, optical, physical, and microenvironmental stimuli provide distinct control strategies. Conditional activation may reduce off‐target exposure and basal nuclease activity.
Ziliang Ding, Yukun Wei, Yong Han, Pengfei Gu   +3 more
wiley   +1 more source

Liver-specific delivery of MDM2 antisense oligonucleotides counteracts diet-induced metabolic-dysfunction-associated steatotic liver diseases. [PDF]

Mol Ther Nucleic Acids
Hoque MM, Kong M, Yuan X, Zhou X, Ting-Yuan Yeh S, Long K, Lin H, Yip Cheng KK.   +7 more
europepmc   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Targeting FANCM using the antisense oligonucleotides to treat the ALT-positive cancers. [PDF]

Mol Ther Nucleic Acids
Naji S, Tong C, Ragupathi A, Xiao M, Zhang D.   +4 more
europepmc   +1 more source

Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases. [PDF]

Mol Ther
Torres-Masjoan L, Aguti S, Zhou H, Muntoni F.   +3 more
europepmc   +1 more source

The impact of chemical modifications of antisense oligonucleotides on CTX-M-15 β-lactamase target affinity and expression of ceftriaxone-resistant <i>Escherichia coli</i>. [PDF]

NAR Mol Med
Barry H, Scillia L, Gaubert A, Amrane S, Vialet B, Bégu D, Barthélémy P, Arpin C, Kauss T.   +8 more
europepmc   +1 more source

Identifying antisense oligonucleotides for targeted inhibition of insulin receptor isoform A. [PDF]

Front Oncol
Galifi CA, Dikdan RJ, Kantak D, Bulatowicz JJ, Maingrette K, Gunderson SI, Wood TL.   +6 more
europepmc   +1 more source

Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications. [PDF]

Mol Ther Nucleic Acids
Kuroda T, Yoshioka K, Mon SSL, Katsuyama M, Sato K, Isogai E, Yoshida-Tanaka K, Iwata-Hara R, Yamaguchi T, Obika S, Yokota T.   +10 more
europepmc   +1 more source

Inhibition of calreticulin by protein nanoparticles carrying antisense oligonucleotides reduce gene expression and infection of <i>Trypanosoma cruzi</i> trypomastigotes on mammalian cells. [PDF]

Nanomedicine (Lond)
Prestegui-Martel B, Martínez I, Cárdenas-Guerra RE, Cortés-Coss AK, Del Toro-Ríos X, Hernández-Garcia A, Espinoza B.   +6 more
europepmc   +1 more source